News & Updates

Treatment with dupilumab appears to be safe and effective in the treatment of patients with bullous pemphigoid (BP), yielding significant improvements in symptoms with a favourable safety profile, according to a study.

Using deep brain stimulation (DBS) to target the cerebellar dentate nucleus appears to be a promising approach for treating patients with poststroke motor impairment, with a first-in-human trial showing that the intervention is safe and yields meaningful improvements in motor function when combined with physical therapy.

Use of anticoagulants during continuous kidney replacement therapy (CKRT) helps lower dialysis dependence and prevent death at 90 days among critically ill patients with acute kidney injury (AKI) following admission to the intensive care unit (ICU), a study in Singapore has shown.

Folic acid appears beneficial in improving sexual function among postmenopausal women, suggests a recent study. However, further research is needed to validate this finding.

For patients who undergo adalimumab tapering after achieving remission, factors such as age, race, and duration of disease remission on adalimumab appear to impact the risk of relapse, according to a study.

Treatment with tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for type 2 diabetes, leads to substantial reductions in weight despite an increase in gastrointestinal symptoms, according to the results of a meta-analysis.

The FDA-approved intrauterine vacuum-induced haemorrhage-control device rapidly controls bleeding in both vaginal and caesarean births, with a safety profile consistent with that observed in the registrational trial, as shown in a postmarket registry medical record review study.

Use of e-cigarette (EC) shows a significant relation with a higher incidence of chronic stress and is indicative of poorer quality of life (QoL) in young adults, suggests a study presented at ERS 2023.

In the treatment of patients with 3-vessel coronary artery disease (CAD), fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) does not differ from coronary artery bypass grafting (CABG) in terms of the incidence of the composite of death, myocardial infarction (MI), or stroke, according to 3-year data from the FAME 3* trial.